37 recruiting. 37 Phase 2, 3 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 37 | Recruiting 37 |
| Phase 1 | 3 | Recruiting 3 |
Follow Immunotherapy: new trials by email Literature Review of Immunotherapy trials Research Report on Immunotherapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PULSAR Radiotherapy Combined With Immunotherapy for High-Risk Advanced Liver Cancer PULSAR (Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy), Immune checkpoint inhibitor-based therapy - Hepatocellular Carcinoma (HCC), Radiotherapy-Induced Immune Priming | Phase 2 | Recruiting | Samsung Medical Center | 38 | 2026-10-15 | 2026-10-21 |
| Biolosion Combined Standard Neoadjuvant Therapy to Treat Triple-negative Breast Cancer Biolosion (oral probiotic compound preparation) - Breast Cancer, Triple Negative Breast Cancer (TNBC) | Phase 2 | Recruiting | Sun Yat-sen University | 192 | 2026-04-01 | 2026-04-01 |
| Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer Systemic immunotherapy - Bladder Cancer, Liquid Biopsy | Phase 2 | Recruiting | Tianjin Medical University Second Hospital | 53 | 2026-03-16 | 2026-05-26 |
| Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer CRT+PD-1 inhibitor+Probio-M9, CRT+PD-1 inhibitor+placebo - Rectal Cancer, Adenocarcinoma, Neoadjuvant Therapy | Phase 2 | Recruiting | Seventh Medical Center of PLA General Hospital | 50 | 2026-02-10 | 2026-03-10 |
| A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer Short-course radiotherapy, Capecitabine, Oxaliplatin - Rectal Cancer, Radiotherapy | Phase 2 | Recruiting | Tao Zhang | 25 | 2026-01-01 | 2026-04-23 |
| A Multicenter, Randomized Controlled Phase II Study of Short-Course Radiotherapy Followed by Sequential PD-1 Inhibitor and FOLFOX Chemotherapy Versus Long-Course Chemoradiotherapy for High-Risk Locally Advanced pMMR/MSS Lower Rectal Adenocarcinoma (STAR Trial) Short-course Radiotherapy, SCRT, Toripalimab - Rectal Adenocarcinoma, High-risk Locally Advanced | Phase 2 | Recruiting | Sixth Affiliated Hospital, Sun Yat-sen University | 76 | 2026-01-01 | 2026-06-25 |
| Phase II Study of Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron for Recurrent Ovarian Cancer Weekly Paclitaxel/Nab-Paclitaxel, Pembrolizumab, and Mirabegron - Ovarian Cancer, Immunotherapy | Phase 2 | Recruiting | Obstetrics & Gynecology Hospital of Fudan University | 20 | 2025-12-01 | 2025-12-19 |
| A Study of ABT-301 Plus Tislelizumab With Bevacizumab in pMMR/Non-MSI-H Locally Advanced or mCRC ABT-301, Tislelizumab, Bevacizumab (Avastin) - Colorectal Cancer (Diagnosis), Colorectal Cancer Metastatic | Phase 1 / Phase 2 | Recruiting | Anbogen Therapeutics, Inc. | 66 | 2025-11-01 | 2025-11-24 |
| Iparomlimab and Tuvonralimab Combined With Apatinib and Irinotecan Hydrochloride for the Treatment of Advanced Alpha-fetoprotein-producing Gastric Cancer (AFPGC) Iparomlimab and Tuvonralimab Injection (QL1706) - AFP Gastric or Gastroesophageal Junction Adenocarcinoma, PD-1/CTLA-4 | Phase 2 | Recruiting | Hebei Medical University Fourth Hospital | 39 | 2025-09-28 | 2025-12-17 |
| Hypofractionated Radiotherapy Combined With Immunochemotherapy for Conversion Treatment of Gastroesophageal Junction Adenocarcinoma hypofractionated radiotherapy, SOX Chemotherapy, PD-1 inhibitor - Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy | Phase 1 / Phase 2 | Recruiting | West China Hospital | 88 | 2025-09-15 | 2025-11-28 |
| SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC PD-1 inhibitor based immunotherapy - Rectal Cancer, Rectal Adenocarcinoma | Phase 2 | Recruiting | Ruijin Hospital | 104 | 2025-09-05 | 2025-09-30 |
| Iparomlimab/Tuvorlimab (QL1706) and Modified TPF Regimen for Induction Therapy in LANPC Iparomlimab/Tuvorlimab(QL-1706) and modified TPF regimen - Locally Advanced Nasopharyngeal Carcinoma, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Xiamen University | 30 | 2025-07-30 | 2025-07-25 |
| BITS-TO-HCC Study: HAIC+Iparomlimab/Tuvonralimab + Bevacizumab + Surgery/SBRT for BCLC-C HCC With PVTT and/or Oligometastases Anti-VEGF, Immunotherapy, Local Therapy - Hepatocellular Carcinoma, Portal Vein Tumor Thrombus | Phase 2 | Recruiting | Shandong Cancer Hospital and Institute | 54 | 2025-07-25 | 2026-10-15 |
| Neoadjuvant Radiotherapy Plus Tegafur, Oxaliplatin and Iparomlimab and Tuvonralimab in Resectable Gastric and GE-junction Cancer : A Randomized, Two-arm, Prospective Trial (TRIUNITE-05) Iparomlimab and Tuvonralimab, Oxaliplatin, Tegafur - Immunotherapy, Gastric Cancer (GC) | Phase 2 | Recruiting | Daping Hospital and the Research Institute of Surgery of the Third Military Medical University | 40 | 2025-07-23 | 2025-09-10 |
| Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA) Fecal microbiota transfer, Vancomycin Oral Capsule, Atezolizumab + Bevacizumab - Immunotherapy, HCC - Hepatocellular Carcinoma | Phase 2 | Recruiting | Michael Dill | 48 | 2025-07-16 | 2025-08-06 |
| The Safety and Clinical Efficacy of RAK Cell Therapy in Late-stage Gastric Cancer: A Randomized Controlled Trial RetroNectin active Killer cells, TAS-102 (trifluridine and tipiracil, Lonsurf®) - Gastric (Stomach) Cancer, Biological Therapy | Phase 2 | Recruiting | Chinese PLA General Hospital | 90 | 2025-07-01 | 2025-10-08 |
| Full-Course Immunotherapy Consolidation for Unfit or Fit B-ALL Who Decline Chemotherapy Blinatumomab and Inotuzumab Ozogamicin - Acute Lymphoblastic Leukemia, Immunotherapy | Phase 2 | Recruiting | The First Affiliated Hospital of Soochow University | 26 | 2025-05-17 | 2026-03-24 |
| Phase II Study of Serplulimab Combined with First-Line Targeted Therapy, Chemotherapy, and Radiation in Advanced Colorectal Cancer Serplulimab, Chemotherapy, SABR - Advanced Colorectal Carcinoma, Immunotherapy | Phase 2 | Recruiting | Fudan University | 208 | 2025-03-01 | 2025-03-14 |
| The Efficacy and Safety of Narlumosbart in Combination With Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined With Immunotherapy in Patients With Bone Metastases From Advanced Non-small Cell Lung Cancer Narlumosbart, Stereotactic Body Radiation Therapy - NSCLC, Stereotactic Body Radiation Therapy (SBRT) | Phase 2 | Recruiting | Fudan University | 27 | 2025-02-15 | 2026-09-11 |
| Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer First-line Immunotherapy Combined with Chemoradiotherapy for ES-SCLC - SCLC, Extensive Stage, Immunotherapy | Phase 2 | Recruiting | Peking University Cancer Hospital & Institute | 60 | 2025-01-07 | 2026-08-17 |
Showing 20 of 37. Sign in to see all of them.
Esophageal Neoplasms (4) · Rectal Neoplasms (4) · Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Stomach Neoplasms (3) · Breast Neoplasms (2) · Colorectal Neoplasms (2) · Adenocarcinoma of Lung (1) · Brain Neoplasms (1) · Disease (1) · Esophageal Squamous Cell Carcinoma (1) · Ovarian Neoplasms (1) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (1) · Triple Negative Breast Neoplasms (1) · Urinary Bladder Neoplasms (1)
Neoplasms (26) · Neoplasms by Site (25) · Digestive System Diseases (17) · Digestive System Neoplasms (17) · Gastrointestinal Diseases (14) · Gastrointestinal Neoplasms (14) · Intestinal Diseases (6) · Intestinal Neoplasms (6) · Neoplasms by Histologic Type (6) · Rectal Diseases (6) · Carcinoma (5) · Esophageal Diseases (5) · Head and Neck Neoplasms (5) · Neoplasms, Glandular and Epithelial (5) · Adenocarcinoma (4)
Bevacizumab (5) · Cisplatin (4) · Drug Therapy (4) · Chemoradiotherapy (3) · pembrolizumab (3) · sintilimab (3) · 130-nm albumin-bound paclitaxel (2) · Carboplatin (2) · Immune Checkpoint Inhibitors (2) · Immunotherapy (2) · Oxaliplatin (2) · Pemetrexed (2) · Radiosurgery (2) · Radiotherapy (2) · atezolizumab (2)
Cancer Institute and Hospital, Chinese Academy of Medical Sciences (3) · Shandong Cancer Hospital and Institute (3) · Sun Yat-sen University (3) · Fudan University (2) · The First Affiliated Hospital of Xiamen University (2) · Anbogen Therapeutics, Inc. (1) · Chinese PLA General Hospital (1) · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University (1) · Fujian Medical University Union Hospital (1) · Hebei Medical University Fourth Hospital (1) · Hunan Province Tumor Hospital (1) · Michael Dill (1) · Nanfang Hospital, Southern Medical University (1) · Obstetrics & Gynecology Hospital of Fudan University (1) · Peking University Cancer Hospital & Institute (1)
China (34) · Australia (1) · Germany (1) · South Korea (1) · Taiwan (1)
Bin Wang (1) · Jin Bo Yue (1) · Jinbo Yue, Doctor (1) · Lei Zhao (1) · Michael T Dill, PhD (1) · Sheng-Li Xue, M.D. (1) · Weiwei Xiao, M.D. (1) · Xin Wang (1) · Yanxia Shi, Doctor (1) · Yong Yang, MD (1) · Yongchang C Zhang, MD (1) · Yongling Ji (1) · Zhenyu Lin (1)
PMID 40348946, PMID 40503038, PMID 40930564, PMID 42206059, PMID 42320986, PMID 42502358, PMID 42823111